Scholarlink

<p>Pancreatic cancer remains a highly lethal malignancy with limited therapeutic options, calling for innovative discovery of efficacious antitumor strategies. Here, we report on PCa2, an AI-derived anticancer lead peptide originating from the <i>Candida albicans</i> genome, which exhibits potent antitumor activity against pancreatic cancer both <i>in vitro</i> and <i>in vivo.</i> Mechanistic investigations suggest that PCa2 is associated with modulation of the ErbB–PI3K–AKT–mTOR–MYC signaling axis, accompanied by receptor internalization and lysosome-mediated degradation. Collectively, these findings identify PCa2 as a promising therapeutic lead candidate that modulates the ErbB–PI3K–AKT–mTOR-MYC axis and induces autophagy-associated cytotoxicity in pancreatic cancer.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An AI-derived peptide PCa2 suppresses pancreatic cancer growth via modulation of the ErbB/PI3K/AKT/mTOR/MYC signaling axis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Weimin Zuo,
  • Siyuan Luo,
  • Haixin Qin,
  • Koon Ho Wong,
  • Shirley W. I. Siu,
  • Alexandre K. Tashima,
  • Yehuda G. Assaraf,
  • Hang Fai Kwok

摘要

Pancreatic cancer remains a highly lethal malignancy with limited therapeutic options, calling for innovative discovery of efficacious antitumor strategies. Here, we report on PCa2, an AI-derived anticancer lead peptide originating from the Candida albicans genome, which exhibits potent antitumor activity against pancreatic cancer both in vitro and in vivo. Mechanistic investigations suggest that PCa2 is associated with modulation of the ErbB–PI3K–AKT–mTOR–MYC signaling axis, accompanied by receptor internalization and lysosome-mediated degradation. Collectively, these findings identify PCa2 as a promising therapeutic lead candidate that modulates the ErbB–PI3K–AKT–mTOR-MYC axis and induces autophagy-associated cytotoxicity in pancreatic cancer.

Graphical abstract